Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development

ABSTRACT Tumor cells utilize glucose as a primary energy source and require ongoing lipid biosynthesis for growth. Expression of DecR1, an auxiliary enzyme in the fatty acid β-oxidation pathway, is significantly diminished in numerous spontaneous mammary tumor models and in primary human breast cancer. Moreover, ectopic expression of DecR1 in ErbB2/Neu-induced mammary tumor cells is sufficient to reduce levels of ErbB2/Neu expression and impair mammary tumor outgrowth. This correlates with a decreased proliferative index and reduced rates of de novo fatty acid synthesis in DecR1-expressing breast cancer cells. Although DecR1 expression does not affect glucose uptake in ErbB2/Neu-transformed cells, sustained expression of DecR1 protects mammary tumor cells from apoptotic cell death following glucose withdrawal. Moreover, expression of catalytically impaired DecR1 mutants in Neu-transformed breast cancer cells restored Neu expression levels and increased mammary tumorigenesis in vivo. These results argue that DecR1 is sufficient to limit breast cancer cell proliferation through its ability to limit the extent of oncogene expression and reduce steady-state levels of de novo fatty acid synthesis. Furthermore, DecR1-mediated suppression of tumorigenesis can be uncoupled from its effects on Neu expression. Thus, while downregulation of Neu expression may contribute to DecR1-mediated tumor suppression in certain cell types, this is not an obligate event in all Neu-transformed breast cancer cells.

[1]  J. Swinnen,et al.  Increased lipogenesis in cancer cells: new players, novel targets , 2006, Current opinion in clinical nutrition and metabolic care.

[2]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[3]  F. Abdul-Karim,et al.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors , 2006, Oncogene.

[4]  W. Muller,et al.  The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation , 2005, Oncogene.

[5]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[6]  Daohai Zhang,et al.  Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer* , 2005, Molecular & Cellular Proteomics.

[7]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[8]  R. Keri,et al.  Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice , 2005, Oncogene.

[9]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[10]  M. Blaufox,et al.  Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. , 2005, Cancer research.

[11]  E. Jaffee,et al.  Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice , 2005, Oncogene.

[12]  Michael Peacock,et al.  Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma , 2004, Clinical Cancer Research.

[13]  W. Muller,et al.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.

[14]  S. Ropero,et al.  Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[16]  D. Huntsman,et al.  The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis , 2004, Modern Pathology.

[17]  V. Anderson,et al.  The mechanism of dienoyl-CoA reduction by 2,4-dienoyl-CoA reductase is stepwise: observation of a dienolate intermediate. , 2001, Biochemistry.

[18]  M. Moran,et al.  Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.

[19]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Kuhajda.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. , 2000, Nutrition.

[21]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[22]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[23]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[24]  G. Pasternack,et al.  Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. , 1996, Cancer research.

[25]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[26]  R. Brown,et al.  GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. , 1995, Anticancer research.

[27]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[29]  K. Cianflone,et al.  Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. , 1990, Journal of lipid research.

[30]  D. Millington,et al.  2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. , 1990, The Journal of clinical investigation.

[31]  M. Ookhtens,et al.  Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. , 1984, The American journal of physiology.

[32]  I. Chaikoff,et al.  Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. , 1967, Cancer research.

[33]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[34]  Ding Li,et al.  Structure and Reactivity of Human Mitochondrial 2,4-Dienoyl-CoA Reductase ENZYME-LIGAND INTERACTIONS IN A DISTINCTIVE SHORT-CHAIN REDUCTASE ACTIVE SITE* , 2005 .

[35]  A. Chinnaiyan,et al.  Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. , 2003, Cancer research.